SUMMARY. Nonstructural protein 5A (NS5A) of the hepatitis C virus (HCV) may repress the interferon (IFN)-induced protein kinase R (PKR). High variability of different regions in the carboxy-terminal half of NS5A implicated in the interaction with PKR (particularly the interferon sensitivity determining region (ISDR)) may be a predictor of response to IFN in patients infected with genotype 1b of HCV. We examined pretreatment serum samples from 17 HCV-1b infected patients included in the same schedule of IFN therapy. Seven patients were a rare series of sustained responders (SR) with a post-treatment follow-up of 5-7 years, while ten were nonresponders (NR). The carboxy-terminal half of the NS5A gene was amplified and directly sequenced in all 17 cases. In addition, the entire NS5A gene and the part of the HCV E2 gene coding for the hypervariable region 1 (HVR1) were amplified, cloned and sequenced in six cases (three NR and three SR). No difference in number and distribution of amino acid mutations was observed between isolates from SR and NR in any portion of the protein, including the ISDR region. Analysis of full length NS5A confirmed no difference between the two groups. The NS5A gene sequence was different among the six cases cloned although it appeared to be conserved in each individual patient independently of the quasispecies complexity evaluated through HVR1 examination. These data indicate that pretreatment analysis of the NS5A genomic variability has no value in predicting long-lasting response to IFN therapy in HCV-1b-infected patients, and that the HCV NS5A gene has high quasispecies homology.
INTRODUCTION
Hepatitis C virus (HCV), a small-enveloped virus with a positive-stranded RNA genome of approximately 9.5 kilobases, is a major cause of chronic liver disease world-wide [1] [2] [3] . Up to 60-80% of infected patients develop a chronic infection that may lead to cirrhosis and even to hepatocellular carcinoma over a period of 10-30 years [2] [3] [4] [5] [6] . Despite the recent therapeutic progress obtained by the use of either inteferon-alpha (IFN-a) in combination with Ribavirin or Pegylated Interferon, more then 50% of patients with chronic C hepatitis still do not respond to therapy, and this percentage significantly increases in cases of infection with genotype 1b HCV (HCV-1b) [7] [8] [9] [10] [11] . The mechanisms involved in the failure of therapy in so many cases are unknown. In the past few years, several groups looking for the identification of factors responsible for resistance to IFN therapy focused their attention on the HCV genomic regions able to interfere with the protein kinase R (PKR) that is an interferon-induced cellular protein with relevant antiviral properties. In particular, in vitro experiments showed that a portion of the NS5A viral protein, the so-called interferon sensitive determining region (ISDR) comprised amino acids (aa) 2209 to aa 2274, is able to bind PKR and to inhibit its activity [12, 13] . Consequently, viruses carrying a modified ISDR sequence might lose their ability to bind the PKR becoming more sensitive to IFN therapy. This hypothesis is in accordance with a number of studies coming in particular from Japan and suggesting that patients infected by HCV-1b strains with high variability at ISDR level -four or more aa changes -may be predicted to have a favourable response to IFN treatment [14] [15] [16] [17] [18] . Nevertheless, contrasting data have been published on this issue [19] [20] [21] [22] [23] . Heterogeneity of other portions of the carboxyl terminus half of NS5A gene was indicated as a factor potentially able to interfere with the capacity of the HCV to abolish the PKR activity, and in particular the entire PKR-binding site (ISDR plus 26 aa downstream) [24] and the so-called V3 region (aa sequences 2356-2379) [25] . However, available data do not clarify whether there is any correlation between variability of these genomic regions and response to IFN therapy. More recently, an in vitro study showed that a 12 amino acid sequence in the E2 gene of HCV-1b is also capable of interacting and inhibiting PKR activity through its high homology with both the PKR autophosphorilation site and the eIF2a phosphorilation site, which is a target of the PKR [26] . It has been postulated that this motif, named PePHD, may be involved in the mechanisms of in vivo resistance to therapy and that its variability may account for cases of positive response. Again, however, clinical investigations have provided controversial data [27, 28] .
The reasons for these discrepancies are difficult to explain, although divergences among different studies both in selection of patients and in virological analyses are still considered a possible explanation [29] .
The aim of this study was to verify whether pretreatment analysis of HCV NS5A gene variability may be a reliable predictor of response to IFN therapy in patients with chronic HCV-1b hepatitis. We therefore extensively investigated the heterogeneity of all viral genomic regions suspected of interfering with PKR activity by the examination of HCV isolated from a group of nonresponders and a rare series of long-lasting sustained responders to therapy.
METHODS

Patients
We retrospectively studied pretreatment serum samples from 17 patients with HCV-1b infection and chronic liver disease without any histological feature of cirrhosis. All patients had been included in a therapeutic schedule consisting of 6 mU of IFN-a given three times weekly for the initial 4 months followed by 3 mU of IFN-a given three times weekly for 8 months. Seven subjects (three men, four women; median age 53 years, range 38-65) were a series of patients with a long-lasting sustained response (SR) to IFN shown by persistent HCV-RNA negativity and normal aminotransferase (AT) values from 5 to 7 years after stopping therapy. The post-treatment biochemical and virological analyses were performed monthly for the first six months of follow-up, every three months for the subsequent two years, and then every six months. Moreover, a percutaneous needle liver biopsy was performed from 18-60 months during the post-treatment follow-up in five of the seven SR showing histological recovery in all cases. Ten patients (five men and five women; median age 52 years, range 40-64) were randomly selected among nonresponders (NR) to therapy (persistence of AT levels and HCV-RNA positivity after 4 months of treatment). None of the patients had signs of excess alcohol intake or use of intravenous drugs, and none were infected either by hepatitis B virus (HBV) nor by human immunodeficiency virus. The only appreciable difference between the two groups was that the pretreatment viremia levels were significantly lower in SR compared to NR (451.105 ± 278.426 vs 8.283.812 ± 5.639.058 copies ⁄ mL, respectively, t ¼ 3.67 P < 0.01).
Serum samples from each patient had been collected just before starting treatment and immediately stored at )80°C for subsequent molecular analyses.
The study protocol was performed according to the principles of the Declaration of Helsinki and informed consent was obtained in every case.
HCV-RNA assays
Serum samples from each patient were tested for HCV-RNA by Amplicor TM HCV 2.0 (Roche, Basel, Switzerland) and quantified by the Roche Amplicor HCV Monitor TM vs 2.0 (Roche). All cases were genotyped by restriction fragment length polymorphism analysis [19] .
Amplification of the carboxyl-terminus portion of the HCV NS5A gene RNA was extracted from 100 lL of serum of each patient as previously described [19] . The portion of NS5A gene coding for protein amino acid sequence 2197-2419 (NS5A 2197-2419 ) and comprising all regions theoretically capable of interfering with the PKR were amplified by reverse-transcription polymerase chain reaction (RT-PCR) in all cases as follows: after reverse transcription performed with antisense primer HCV-1.5 lL of the cDNA was heated at 94°C for 2 min and amplified in a final volume of 50 lL containing 50 mm potassium chloride, 10 mm TRIS-hydrochloric acid (pH 8.3), 1.5 mm magnesium chloride, 200 lm of each four deoxyribonucleosides, 2.5 U of Expand High Fidelity Taq Polymerase (Roche Diagnostic Corporation, Indianapolis, IN, USA) and 20 pmoL each of the oligonucleotide primers HCV-1 and HCV-2 with 100 lL of mineral oil. Nested PCR amplification was performed with 4 lL from the product of the first reaction and the inner primers HCV-3 and HCV-4. First round amplification was performed for 35 cycles, consisting of denaturing for 30 s at 94°C, annealing for 45 s at 62°C and extension for 1 min at 68°C. The second round of PCR was performed with the above mentioned conditions except for an annealing temperature of 64°C. Products of amplification were electrophoresed in ethidium bromide stained 2% agarose gel, cut out from gel and purified by minicolumn system (QIAquick Gel Extraction Kit, Quiagen, Hilden, Germany). The purified products were directly sequenced in both strands by the ABI PRISM 310 Genetic sequence analyser using ABI PRISM dye terminator cycle sequencing ready reaction kit (Applied Biosystems, Applera Europe B.V., Nieuwerkerk ad Jssel, the Netherlands).
Cloning of HCV NS5A gene and E2 hypervariable region 1
Intraindividual HCV variability is referred to as a quasispecies, which is usually evaluated through the analysis of the hypervariable region 1 (HVR1) of the E2 gene.
To further examine the NS5A gene heterogeneity and to investigate its variability in relation with the quasispecies complexity in individual cases, the entire NS5A gene coding for protein comprised between amino acid positions 1973-2419 and the HVR1 of E2 gene were amplified by RT-PCR in six cases, three cases randomly chosen from the NR group and three cases from the SR group. The NS5A 1073-2419 was amplified with the above mentioned conditions and the oligonucleotide outer primers HCV-5 ⁄ HCV-1 and inner primers HCV-6 ⁄ HCV-4. First round amplification was performed for 35 cycles, consisting of denaturing for 60 s at 94°C, annealing for 1.5 min at 62°C and extension for 2.5 min at 68°C. Conditions of the second round PCR were identical to those of first round amplification except for an annealing temperature of 66°C.
RT-PCR of HVR1 was performed with outer and inner primers HCV-7 ⁄ HCV8 and HCV9 ⁄ HCV10, respectively. First round amplification was performed for 35 cycles, consisting of denaturing for 15 s at 94°C, annealing for 30 s at 62°C and extension for 1.5 min at 68°C. Conditions of the second round PCR were identical to those of first round amplification except for an annealing temperature of 66°C.
The products of amplification comprising the NS5A gene sequence and those of the HVR1 region were cloned into TOPO TA Cloning v 1.0 (Invitrogen BV, Groningen, the Netherlands). Ten clones of NS5A and ten clones of HVR1 of each case were sequenced following the above mentioned procedures.
Amplification of the HCV PePHD motif in the E2 gene
RT-PCR for the PePHD motif (aa 665-676) was performed on RNA extracts from all 17 cases following the above-mentioned procedures and the oligonucleotide outer and inner primers HCV-11 ⁄ HCV12 and HCV13 ⁄ HCV14, respectively. First round amplification was performed for 35 cycles consisting of denaturing for 45 s at 94°C, annealing for 45 s at 62°C and extension for 60 s at 72°C. Conditions of the second round PCR were identical to those of the first round amplification except for an annealing temperature of 66°C. Products of amplification were sequenced as reported above.
All the obtained sequences were aligned and compared with those published in GenBank (National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD, USA).
The nucleotide primers used for amplification and sequencing analyses had the following 5¢ and 3¢ nucleotide positions according to the prototype HCV-J complementary DNA [30] 
Statistical analysis
Statistical evaluations were made by the student's t-test and the Chi Square test.
RESULTS
Carboxl terminus portion of the HCV NS5A gene (aa 2197-2419)
The NS5A 2197)2419 deduced amino acid sequences of the 17 cases are shown in Fig. 1 . The amino acid sequences from the seven SR and from the ten NR were different from each other and all differed from the HCV-J prototype for five amino acids located at positions 2259 (I fi L), 2262 (V fi E), 2318 (S fi P), 2367 (G fi A), 2387 (E fi S), as previously described in HCV-1b strains from European patients [23] . The median of amino acid substitutions was, respectively, 18 (range [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] in SR and 19 (range [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] in NR. In particular we found no significant difference in the ISDR region between the two groups, and none of the cases, either SR or NR, were mutant type with more than four amino acid substations according to Enomoto's classification [13] . The remaining part of the NS5A PKR binding site showed higher variability than the ISDR part in all cases, irrespective of the response to therapy (from 2-5 aa changes with a median of three substitutions both in SR and NR groups). In analogy, the V3 region appeared to be highly heterogeneous, although no significant difference was found between the two groups studied (median of four amino acid changes in both groups, range 3-7 in SR and 3-6 in NR). In addition, the evaluation of other amino acid residues considered of relevance for NS5A protein functions as phosphorilation sites (serine at positions 2194, 2197, 2201, 2204) and the nuclear localization signal located between amino acid 2326 and 2334 showed very high homology between the two groups.
HCV PePHD analysis
None of the 12 amino acid residues of this region were mutated in any of the 17 cases (data not shown).
Cloning analyses of full length NS5A gene and HVR1
Analysis of clones of the entire NS5A gene from three SR and three NR confirmed no significant difference between the two groups [ Fig. 2 ]. In addition, low grade genomic diversity was observed among the ten clones examined from each individual case, as shown in Fig. 2 . In particular, the ISDR region of none of the clones examined was ÔmutantÕ type with four or more amino acid changes.
On the contrary, the analysis of HVR1 clones showed high quasispecies diversity in most cases (nine, nine and eight different variant strains in the three SR and three, six and five variants in the three NR, respectively) [ Fig. 3 ].
DISCUSSION
HCV-1b is the most prevalent HCV subtype world-wide, and much evidence suggests that it is less sensitive to IFN compared to other subtypes [3, 31] . It has been hypothesized that HCV-1b has developed peculiar strategies by which it may evade the antiviral action of either endogenous or exogenous IFN [27, 32] . The viral NS5A protein seems to play a central role in the molecular mechanisms of resistance to IFN, possibly through its capacity to bind and to repress the cellular PKR protein kinase that is a mediator of the IFN-induced antiviral response of the host [12] . The ISDR is a discrete region of 40 amino acids included in the PKR binding domain of the NS5A protein, and there is evidence that isolates with high rates of amino acid mutations at this level may lose the capacity to bind and inhibit the PKR and become sensitive to IFN. More recently, a number of reports have suggested that the variability of other portions of the carboxy-terminal half of the NS5A might interfere with the ability of this protein to bind the PKR, thus possibly influencing the NS5A anti-IFN activity [24, 25] . A close relationship between the response to IFN therapy and multiple amino acid mutations ( ‡ 4) in the ISDR region of isolates from HCV-1b-infected patients was firstly reported by Enomoto et al. [15] , and subsequently confirmed by other Japanese studies [16, 17] . On the contrary, most of the European and North American studies denied the association (reviewed in 29 and 33). Despite these contradictory data, in the past few months several papers have been published claiming the clinical usefulness of ISDR sequence analysis for the prediction of response to IFN therapy in individual HCV-1b-infected patients [34] , and a method has also been proposed for easy application of this test in diagnostic practice [35] .
The above-mentioned discrepancy between Japanese and Western studies is difficult to interpret. A role played by racial differences or by diversity between the HCV-1b strains spread in Japan compared to those commonly found in the Western world has been postulated [19] , but these hypotheses have not been confirmed. One explanation may be the existence of methodological biases concerning either the selection of patients, the therapeutic regimens, or the generation and extension of NS5A sequences [29] .
All patients in our study had been included in the same schedule of treatment with IFN. Nonresponders were defined as those subjects that showed persistently positive HCV-RNA and abnormal liver biochemistry after 4 months of therapy. We paid particular attention to the choice of responders to be included in the study: they were a unique series of seven HCV-1b-infected patients with 5-7 years of post-treatment follow-up and with virological, biochemical and histological evidence of true long-term response (cured?) to IFN. Finally, we examined the carboxyl terminus of the NS5A gene in all patients, including all regions suggested as being implicated in the interaction with PKR in isolates from each patient; in addition, the entire NS5A gene was analysed by cloning and sequencing procedures in six randomly selected cases (three SR and three NR).
The comparative examination of the 17 NS5A genes and the deduced amino acid sequences showed no significant difference between responder and nonresponder patients either in terms of total number of mutations or in terms of distribution of the mutations in the different parts of the protein. In particular, the ISDR sequences were comparable in the two groups of patients, and mutant viruses carrying four or more amino acid changes were detected in none of the cases even when cloning products were examined. Confirming previous studies, the highest variability was found in the carboxyl terminus end of the protein, in particular at the level of the portion of the PKR-binding site downstream of the ISDR and in the V3 region. These mutation cluster regions did not show any correlation with the type of response to therapy. This high rate of NS5A variability observed in isolates from different subjects was not noticed among viral populations isolated from individual patients, as revealed by sequencing analysis of full-length NS5A clones obtained from each of six cases. However, the low grade of NS5A variability in viral strains from each individual case did not reflect the level of HCV quasispecies diversity since cloning and sequencing analysis of the HVR1 region of viruses from the same six patients showed a high number of variants in most of them. In other words, our data suggest that the NS5A protein is quite heterogeneous among patients, while it is relatively conserved in viral populations infecting individual patients. Finally, it should be mentioned that both the amino terminal end of the NS5A, upstream of the PKR binding site, and the PePHD motif in E2 were highly conserved in all cases examined confirming several previous reports [25, 27, 36] .
In summary, our data showed that isolates from pretreatment sera of HCV-1b-infected patients who were longlasting responders to IFN therapy had no peculiar feature with respect to viruses from nonresponders, either in ISDR or at the level of other NS5A genomic regions postulated to be of relevance in interfering with cellular PKR activity. In particular, we did not find any correlation between degree of amino acid substitution and response to therapy and, consequently, the ISDR sequencing analysis frequently claimed to be important in predicting IFN efficacy in individual patients appears to be of insignificant prognostic value, at least in patients from the western world.
A growing number of in vitro studies are currently providing new insight for the comprehension of the biological properties of the HCV NS5A protein. In fact, it has been shown Fig. 2 Amino acid sequence alignments of the entire NS5A protein of ten clones for each of the three SR (a) and the three NR (b) cases examined. In the NS5A sequence the amino acid positions corresponding to serine residues (2197, 2201, 2204), ISDR region (aa 2209-2248), PKR binding domain (aa 2209-2274), nuclear localization signal (aa 2326-2334), V3 region (aa 2356-2379) are underlined. In each case the clones (CL) are numbered from 1 to 10. Dashes indicate aa residues identical to those found in the clone number 1 that was the first sequenced and is entirely reported. that this protein may interfere with fundamental processes of the mammalian cells, such as proliferation and programmed cell death by its interaction with different cellular proteins [37] [38] [39] [40] . Furthermore, there is evidence that NS5A may inhibit interferon-induced antiviral activity through mechanisms alternative to PKR suppression, such as the interference with either JAK-STAT or ERK or p38 MAPK pathways [reviewed in 29] . Concerning the NS5A interaction with PKR, it must be underlined that the role of ISDR is not yet clarified, and several studies strongly suggest that mutations in that region and even its complete deletion do not significantly affect the antiviral action of the NS5A [41] [42] [43] [44] .
As for other viruses, studies on genetic heterogeneity of HCV are essential for the comprehension of mechanisms implicated in the pathogenesis and resistance to antivirals. However, the hypothesis that sequencing analyses of portions of the viral genome may provide reliable indications for therapeutic choices appears to be improbable for chronic hepatitis C patients considering the number of factors (alcohol intake, iron overload, coinfection by other agents, etc.) that may influence their clinical outcome and response to therapy.
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